Developer docs
API playgroundTry for free, no card

Search company profiles

Stemson Therapeutics

Full company profile

uuid0002dpw

Namestring
Stemson Therapeutics
Websiteurl
stemsontx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Stemson Therapeutics is a pre-clinical stage cell therapy company developing a novel hair follicle cloning approach to treat hair loss conditions, with explicit indication targets including androgenetic alopecia and alopecia areata. The company's scientific premise is that current hair-loss treatments only redistribute or slow the loss of existing hair, whereas Stemson aims to generate new hair follicles de novo using the patient's own cells, representing a regenerative-medicine rather than a cosmetic or transplant-based solution.

The platform is anchored by scientific co-founder and CSO Alexey V. Terskikh and CSO Kevin D'Amour, both with stem cell biology expertise. To date the company has raised approximately $22.5M in aggregate funding, comprising a $7.5M seed round in September 2020 led by Fortunis Capital and a $15M Series A in July 2021 led by DCVC Bio with participation from strategic pharma AbbVie and Genoa Ventures. Headcount is reported at 1-10 employees and the company remains privately held with no products commercialized, no pricing model in place, and no distribution or marketing channels established.

The business model is consistent with an early-stage biotech: value creation is expected to occur through eventual clinical development, regulatory milestones, and either out-licensing, partnership with a large pharmaceutical player, or a trade sale, rather than direct product commercialization in the near term. The company targets an addressable patient population of approximately 80 million people in the US alone affected by androgenetic alopecia.

Short descriptiontext

Stemson Therapeutics is a pre-clinical, privately held cell therapy company developing a novel hair follicle cloning approach using patients' own cells to treat androgenetic alopecia and alopecia areata. Founded in 2018 and based in San Diego, it is led by scientific founders and funded by DCVC Bio, AbbVie, and Fortunis Capital.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
regenerative medicine, cell therapy, hair follicle cloning, alopecia treatment, biopharmaceutical research
Industry2 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Stemson Therapeutics is a pre-clinical stage cell therapy company developing a novel hair follicle cloning approach using cell therapy and regenerative medicine to treat hair loss conditions including androgenetic alopecia and alopecia areata. The company uses the patient's own cells to generate new hair follicles, aiming to provide a biological cure for baldness rather than relying on temporary solutions such as wigs, topicals, or transplanting existing hair. The therapy is currently in clinical development and has not yet been commercialized.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available for Stemson Therapeutics in the provided source data. Stemson Therapeutics is referenced in news articles as a biotech firm developing hair follicle cloning technology through cellular biology and regenerative medicine approaches, with ongoing clinical trials, but no specific product details, names, or service offerings are documented in the available sources.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Portugal-based biotech developing cell-based regenerative therapies for hair loss. Directly comparable to Stemson: pre-clinical cell therapy modality targeting androgenetic alopecia with similar scientific premise of follicle regeneration.

TypeDirect peer
Description

Biotech founded out of Stanford that engineers cells to produce hair growth factors, applying cell and gene therapy approaches to hair loss. Closely comparable modality (cell-based hair regeneration) and stage profile.

3Organ Technologies
TypeDirect peer
Description

Japan-based regenerative medicine company that has pioneered hair follicle regeneration using cell-based approaches in collaboration with RIKEN. Closest Asia-Pacific analog pursuing the same cell-therapy-for-hair-loss thesis as Stemson.

TypeBroad incumbent
Description

Global biopharma with aesthetics/dermatology franchise (via Allergan) marketing hair-related products including Latisse. Already a Stemson investor (Series A 2021), giving it both strategic and financial overlap with the hair-loss treatment space.

TypeBroad incumbent
Description

Markets Olumiant (baricitinib), a JAK inhibitor approved for severe alopecia areata. Competes for the same alopecia patient population Stemson is targeting, representing the current standard-of-care benchmark for advanced medical hair loss treatment.

TypeBroad incumbent
Description

Markets Litfulo (ritlecitinib), a JAK inhibitor approved for severe alopecia areata, plus legacy hair-loss product lines. A broad incumbent competing in Stemson's target indication via an alternative (small-molecule) modality.

TypeBroad incumbent
Description

Large incumbent in dermatology and medical aesthetics with active R&D in hair loss. Represents the kind of strategic acquirer/partner that a successful Stemson clinical readout could attract.

TypeEmerging player
Description

Clinical-stage biotech developing JAK inhibitors and other therapies for alopecia areata and androgenetic alopecia. Emerging competitor focused on a specific use case that overlaps directly with Stemson's target indications.

TypeEmerging player
Description

South Korea-based biotech developing exosome-based regenerative treatments, including for hair loss. Represents an emerging, lower-cost alternative modality that could compete with cell therapy on accessibility and price.

10Bristol Myers Squibb
TypeBroad incumbent
Description

Major cell therapy incumbent (Breyanzi, Abecma) with deep autologous CAR-T manufacturing infrastructure and clinical-translation know-how relevant to scaling an autologous iPSC-based therapy like Stemson's.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stemson Therapeutics

Regenerative Medicinestemsontx.com

Stemson Therapeutics is a pre-clinical, privately held cell therapy company developing a novel hair follicle cloning approach using patients' own cells to treat androgenetic alopecia and alopecia areata. Founded in 2018 and based in San Diego, it is led by scientific founders and funded by DCVC Bio, AbbVie, and Fortunis Capital.

What Stemson Therapeutics does

Stemson Therapeutics is a pre-clinical stage cell therapy company developing a novel hair follicle cloning approach to treat hair loss conditions, with explicit indication targets including androgenetic alopecia and alopecia areata. The company's scientific premise is that current hair-loss treatments only redistribute or slow the loss of existing hair, whereas Stemson aims to generate new hair follicles de novo using the patient's own cells, representing a regenerative-medicine rather than a cosmetic or transplant-based solution.

The platform is anchored by scientific co-founder and CSO Alexey V. Terskikh and CSO Kevin D'Amour, both with stem cell biology expertise. To date the company has raised approximately $22.5M in aggregate funding, comprising a $7.5M seed round in September 2020 led by Fortunis Capital and a $15M Series A in July 2021 led by DCVC Bio with participation from strategic pharma AbbVie and Genoa Ventures. Headcount is reported at 1-10 employees and the company remains privately held with no products commercialized, no pricing model in place, and no distribution or marketing channels established.

The business model is consistent with an early-stage biotech: value creation is expected to occur through eventual clinical development, regulatory milestones, and either out-licensing, partnership with a large pharmaceutical player, or a trade sale, rather than direct product commercialization in the near term. The company targets an addressable patient population of approximately 80 million people in the US alone affected by androgenetic alopecia.

Stemson Therapeutics firmographics

Firmographics
Name
Stemson Therapeutics
Website
https://stemsontx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Stemson Therapeutics is a pre-clinical, privately held cell therapy company developing a novel hair follicle cloning approach using patients' own cells to treat androgenetic alopecia and alopecia areata. Founded in 2018 and based in San Diego, it is led by scientific founders and funded by DCVC Bio, AbbVie, and Fortunis Capital.
Ownership category
akta.pro rank

Stemson Therapeutics industry classification

Industry
Product category
Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Regenerative medicine
  • Cell therapy
  • Hair follicle cloning
  • Alopecia treatment
  • Biopharmaceutical research

Where Stemson Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Stemson Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Stemson Therapeutics product offering

Product offering

Core offering

Stemson Therapeutics is a pre-clinical stage cell therapy company developing a novel hair follicle cloning approach using cell therapy and regenerative medicine to treat hair loss conditions including androgenetic alopecia and alopecia areata. The company uses the patient's own cells to generate new hair follicles, aiming to provide a biological cure for baldness rather than relying on temporary solutions such as wigs, topicals, or transplanting existing hair. The therapy is currently in clinical development and has not yet been commercialized.

Product overview

No product information available for Stemson Therapeutics in the provided source data. Stemson Therapeutics is referenced in news articles as a biotech firm developing hair follicle cloning technology through cellular biology and regenerative medicine approaches, with ongoing clinical trials, but no specific product details, names, or service offerings are documented in the available sources.

Differentiator

Problem solved

Functional benefit

Companies that use Stemson Therapeutics

Customer profile

Ideal customer profiles1 record

Stemson Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Stemson Therapeutics partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Stemson Therapeutics competitors and assessment

Company assessment

Direct peers

  • Stemmatters: Portugal-based biotech developing cell-based regenerative therapies for hair loss. Directly comparable to Stemson: pre-clinical cell therapy modality targeting androgenetic alopecia with similar scientific premise of follicle regeneration.
  • dNovo: Biotech founded out of Stanford that engineers cells to produce hair growth factors, applying cell and gene therapy approaches to hair loss. Closely comparable modality (cell-based hair regeneration) and stage profile.
  • Organ Technologies: Japan-based regenerative medicine company that has pioneered hair follicle regeneration using cell-based approaches in collaboration with RIKEN. Closest Asia-Pacific analog pursuing the same cell-therapy-for-hair-loss thesis as Stemson.

Broad incumbents

  • AbbVie: Global biopharma with aesthetics/dermatology franchise (via Allergan) marketing hair-related products including Latisse. Already a Stemson investor (Series A 2021), giving it both strategic and financial overlap with the hair-loss treatment space.
  • Eli Lilly: Markets Olumiant (baricitinib), a JAK inhibitor approved for severe alopecia areata. Competes for the same alopecia patient population Stemson is targeting, representing the current standard-of-care benchmark for advanced medical hair loss treatment.
  • Pfizer: Markets Litfulo (ritlecitinib), a JAK inhibitor approved for severe alopecia areata, plus legacy hair-loss product lines. A broad incumbent competing in Stemson's target indication via an alternative (small-molecule) modality.
  • Johnson & Johnson: Large incumbent in dermatology and medical aesthetics with active R&D in hair loss. Represents the kind of strategic acquirer/partner that a successful Stemson clinical readout could attract.
  • Bristol Myers Squibb: Major cell therapy incumbent (Breyanzi, Abecma) with deep autologous CAR-T manufacturing infrastructure and clinical-translation know-how relevant to scaling an autologous iPSC-based therapy like Stemson's.

Emerging players

  • Aclaris Therapeutics: Clinical-stage biotech developing JAK inhibitors and other therapies for alopecia areata and androgenetic alopecia. Emerging competitor focused on a specific use case that overlaps directly with Stemson's target indications.
  • ExoCoBio: South Korea-based biotech developing exosome-based regenerative treatments, including for hair loss. Represents an emerging, lower-cost alternative modality that could compete with cell therapy on accessibility and price.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Stemson Therapeutics social profiles

Digital presence

Stemson Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stemson Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Stemson Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stemson Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stemson Therapeutics

What does Stemson Therapeutics do?

Stemson Therapeutics is a pre-clinical stage cell therapy company developing a novel hair follicle cloning approach using cell therapy and regenerative medicine to treat hair loss conditions including androgenetic alopecia and alopecia areata. The company uses the patient's own cells to generate new hair follicles, aiming to provide a biological cure for baldness rather than relying on temporary solutions such as wigs, topicals, or transplanting existing hair. The therapy is currently in clinical development and has not yet been commercialized.

Is Stemson Therapeutics a public or private company?

Stemson Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stemson Therapeutics founded?

Stemson Therapeutics was founded in 2018. It employs 1 to 10 people.

Where is Stemson Therapeutics based?

Stemson Therapeutics is headquartered in San Diego, United States, in the North America region.

Who are Stemson Therapeutics's main competitors?

Direct peers on record are Stemmatters, dNovo and Organ Technologies. Broad incumbents are AbbVie, Eli Lilly, Pfizer, Johnson & Johnson and Bristol Myers Squibb. Emerging players are Aclaris Therapeutics and ExoCoBio.

Does Stemson Therapeutics have an API?

No public API is recorded for Stemson Therapeutics.

What industry is Stemson Therapeutics in?

Stemson Therapeutics's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comRegenerative Medicine Market Size, Growth, Key Players, Latest Insights and Forecast 2026-2034IMARC Group reports that the global Regenerative Medicine Market was valued at USD 31.8 Billion in 2025 and is projected to reach USD 143.3 Billion by 2034, growing at a CAGR of 17.65%. The market expansion is driven by rising chronic disease prevalence, advancements in cell and gene therapies, and increased investment in stem cell research. Key industry developments include partnerships between Aderans Company and Stemson Therapeutics for hair regeneration, as well as funding for Denovo's gene therapy initiatives.Venture Capital Access OnlineStemson Therapeutics Secures $15M Series A Funding to Cure Hair LossStemson Therapeutics closed a $15 million Series A funding round led by DCVC Bio to advance its proprietary hair regeneration technology. The investment, which also includes participation from Genoa Ventures and AbbVie Ventures, brings the company's total raised capital to $22.5 million as it prepares for human clinical trials.PharmiWeb.comAnsa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business OfficerAnsa Biotechnologies announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer, reporting directly to CEO Jason T. Gammack. Hamilton brings over 25 years of leadership experience from life sciences and medical device companies, including co-founding and serving as CEO of Stemson Therapeutics and senior roles at Illumina, Life Technologies, and Stryker. The appointment is aimed at accelerating Ansa's commercial expansion during its first year of commercialization, driven by surging demand for its synthetic DNA products produced via an enzymatic platform.Business Wire BlogStemson Therapeutics and Bosley Parent Company, Aderans, Sign Exclusive Hair Regeneration Licensing DealStemson Therapeutics and Aderans Company have signed an exclusive global licensing agreement granting Stemson the rights to research, develop, and commercialize hair regeneration therapeutics based on Aderans' proprietary cell therapy technology. Stemson will resume Aderans' Phase 2 clinical program for treating Androgenetic Alopecia and integrate it into its existing development pipeline. This deal allows Stemson to leverage complementary technologies to accelerate timelines for creating breakthrough hair loss solutions.Business Wire BlogStemson Therapeutics Announces Technological Breakthrough in New Hair GrowthStemson Therapeutics announced a technological breakthrough in creating engineered functional hair follicles using human-induced pluripotent stem cells, successfully demonstrating hair growth in humanized mice. This development clears the path for the company's proprietary autologous cell therapy to advance toward human clinical trials for treating various forms of alopecia. The company also promoted two executives to support its progression into the final stages of product development.GenengnewsHair Loss Treatment Uses Stem Cells to Generate Healthy New FolliclesStemson Therapeutics is pioneering a treatment for hair loss that uses induced pluripotent stem cells (iPSCs) to regenerate healthy new hair follicles, targeting conditions like androgenic alopecia. The company is currently in preclinical development using mouse and pig models, with plans to advance to human trials after demonstrating consistent results in pigs. Allergan provided early investment support, helping the company overcome initial funding challenges despite the niche nature of the hair loss market.BioSpaceKevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific OfficerStemson Therapeutics appointed Kevin D’Amour as its new Chief Scientific Officer to lead the development of an iPSC-derived cell therapy for hair loss. D’Amour brings over two decades of experience in stem cell therapy, having previously served as CSO at ViaCyte and Brooklyn ImmunoTherapeutics. His appointment is intended to accelerate Stemson's research mission toward clinical advancement.Business Wire BlogPaul Laikind, PhD, Joins Stemson Therapeutics Board of DirectorsStemson Therapeutics announced that Paul Laikind, a seasoned biotech entrepreneur and former CEO of ViaCyte, has joined its Board of Directors. Laikind will provide strategic guidance to support the company's efforts to develop an iPSC-derived cell therapy for hair loss. This appointment aims to accelerate Stemson's progress toward advancing its first product into human clinical trials.BioSpaceStemson Therapeutics Announces Additions To Its Scientific Advisory BoardStemson Therapeutics announced the appointment of Dr. Kapil Bharti and Dr. George Murphy to its Scientific Advisory Board to guide the development of an iPSC-derived cell therapy for hair loss. The additions are intended to leverage the experts' backgrounds in regenerative medicine and skin biology to accelerate the company's pre-clinical research into regenerating new hair follicles. This strategic move supports Stemson's mission to treat alopecia using autologous cells.MIT Technology ReviewGoing bald? Lab-grown hair cells could be on the wayStartups like dNovo and Stemson are using genetic reprogramming to create hair-forming cells from ordinary cells, with dNovo showing a mouse sprouting human hair after a transplant. The technology could treat the underlying cause of hair loss, but more research is needed before clinical use.